Biotechnology firm Infinimmune Inc. on Tuesday entered a collaboration with Merck &amp; Co Inc. (NYSE:MRK) to develop antibody candidates using its human-first discovery platform.



The agreement enables Merck to leverage Infinimmune's proprietary technologies to identify therapies targeting multiple undisclosed programs.



<h2>Merck Secures Exclusive Development And Commercial Rights</h2>



Under the terms, Merck will gain exclusive rights to develop and commercialize antibody candidates generated through the collaboration.



Under the terms of the agreement, Infinimmune will receive an undisclosed upfront payment and is eligible to receive milestone payments associated with the progress of multiple antibody candidates all totaling up to approximately $838 million.



<h2>Platform Combines Human Data And Machine Learning</h2>



Infinimmune will deploy its Anthrobody discovery platform alongside its GLIMPSE antibody language model to identify and optimize therapeutic antibodies derived directly from human immune systems.



The platform enables large-scale screening of millions of single memory B cells across hundreds of targets.



The approach allows for the identification of naturally paired antibodies with strong binding affinity, specificity, and drug-like properties.



<h2>Focus On High-Quality, Human-Derived Therapeutics</h2>



The company integrates single-cell immune repertoire analysis with machine learning–guided engineering to enhance potency, manufacturability, and overall developability of candidates.



Its dataset—one of the largest collections of naturally occurring human antibodies—supports the design of therapies with improved specificity, extended half-life, and lower risk of immunogenicity.



<h2>Pipeline Advances In Immunology And Inflammation</h2>



Beyond the collaboration, Infinimmune continues to advance its internal pipeline. Lead candidates include IFX-101, an IL-22 inhibitor, and IFX-201, an IL-13 inhibitor, both targeting moderate-to-severe atopic dermatitis.



Additional programs focus on inflammatory and immunological conditions, including therapies targeting APRIL and IL-17F, among others.



Most recently, Merck agreed to acquire Terns Pharmaceuticals Inc. (NASDAQ:TERN), as the U.S. drugmaker accelerates efforts to offset looming revenue risks tied to its blockbuster cancer immunotherapy Keytruda.



The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.



MRK Price Action: Merck shares were up 0.34% at $120.70 during premarket trading on Wednesday. The stock is approaching its 52-week high of $125.14, according to Benzinga Pro data.



Image via Shutterstock

ARKG

INMB

Merck & Co Inc. has partnered with Infinimmune Inc. to develop next-generation antibody candidates using Infinimmune's human-first discovery platform. This collaboration grants Merck exclusive rights to develop and commercialize the resulting therapies. Infinimmune will receive an undisclosed upfront payment and could earn up to $838 million in milestone payments based on the progress of multiple antibody candidates. The partnership will leverage Infinimmune's Anthrobody discovery platform, which integrates human data with machine learning.

Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs